



(51) International Patent Classification:

C07D 471/04 (2006.01) *A61K 31/55* (2006.01)
C07D 487/04 (2006.01) *A61P 11/00* (2006.01)
A61K 31/437 (2006.01)

(21) International Application Number:

PCT/IB2012/053546

(22) International Filing Date:

11 July 2012 (11.07.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/512,144 27 July 2011 (27.07.2011) US

(71) Applicant (for all designated States except US): **PFIZER LIMITED** [GB/GB]; Ramsgate Road, Sandwich, Kent, CT13 9NJ (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **COE, Jotham, Wadsworth** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340 (US). **DEHNHARDT, Christoph, Martin** [DE/US]; Pfizer Global Research and Development, 87 Cambridge Park Drive, Cambridge, MA 02140 (US). **JONES, Peter** [GB/US]; Pfizer Global Research and Development, 87

Cambridge Park Drive, Cambridge, MA 02140 (US). **KORTUM, Steven Wade** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340 (US). **SABNIS, Yogesh, Anil** [IN/GB]; c/o Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent, CT13 9NJ (GB). **WAKENHUT, Florian, Michel** [FR/GB]; c/o Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent, CT13 9NJ (GB). **WHITLOCK, Gavin, Alistair** [GB/GB]; c/o Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent, CT13 9NJ (GB).


(74) Agent: **KLEIMAN, Gabriel L.**; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

[Continued on next page]

(54) Title: INDAZOLES



(57) Abstract: The present invention relates to compounds of formula (I) to pharmaceutically acceptable salts therefore and to pharmaceutically acceptable solvates of said compounds and salts, wherein the substituents are defined herein; to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly asthma and COPD.



GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

Declarations under Rule 4.17:

— *as to the identity of the inventor (Rule 4.17(i))*